Embramine


Concise Prescribing Info
Indications/Uses
Allergic conditions.
Dosage/Direction for Use
Adult : PO 25-50 mg/day.
Dosage Details
Oral
Allergic conditions
Adult: 25-50 mg daily.
Child: Same as adult dose.
Elderly:
Contraindications
Urinary or GI tract obstruction, paralytic ileus. Pregnancy and lactation.
Special Precautions
Patient w/ closed-angle glaucoma, prostate enlargement, heart disease, and epilepsy. Childn.
Adverse Reactions
Headache, sleep disorder, hypotension, loss of appetite, asthma, bone marrow depression, constipation, drowsiness, increased sweating, tingling, shock, swelling, wt gain, urinary hesitancy, urinary retention, CNS depression, dry mouth, thickening of resp secretions, blurred vision, GI upset, tinnitus, vertigo, giddiness, nausea, paraesthesia, bradycardia followed by tachycardia and arrhythmias; paradoxical stimulation in childn.
Patient Counseling Information
May impair ability to drive or operate machinery.
Drug Interactions
Additive anti-muscarinic effect w/ MAOIs, TCAs and atropine. Enhances the CNS depressant effect of barbiturates, sedatives, hypnotics, analgesics and neuroleptics. Masks ototoxicity produced by aminoglycosides.
Food Interaction
Enhances the CNS depressant effect of alcohol.
Action
Description: Embramine selectively binds to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
Storage
Store at room temp.
References
Buckingham R (ed). Embramine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/04/2016.

Embramine. National Center for Biotechnology Information. PubChem Database. https://pubchem.ncbi.nlm.nih.gov/. Accessed 15/04/2016 .

Mebryl (GlaxoSmithKline). MIMS India. http://www.mims.com/india. Accessed 15/04/2016 .

Disclaimer: This information is independently developed by MIMS based on Embramine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in